

## Special Commission to Study Switching Medications

Created pursuant to Section 195 of  
Chapter 133 of the Acts of 2016

Thursday, October 12, 2017  
1:00 pm – 3:00 pm  
6th floor, 100 Hancock St, Quincy

### Minutes

---

**Chair:** Paul Jeffrey

**Scribe:** Nancy Schiff

**Commission Members in Attendance:** P Jeffrey, D Schiel, L Stairs, E Kiriakopoulos (phone), S Sadownik (phone), C Griffin (phone), K. Krishnamurthy (phone); D Mauch (phone)

**Commission Members not in Attendance:** P Summergrad

**Others in Attendance:** N Schiff, J Oros (AbbVie), K Bell and D Cahill (BCB Government Relations, Inc.), J Heffernan (Park Street Strategies)

#### Meeting Summary:

1. The minutes were not in the meeting packet, so the group agreed to review the minutes by email.
2. The group discussed the status of the past month's action items and status of deliverables.
3. Analysis
  - a. In order to do the analysis, CHIA needs some clinical input about the pharmacy data.
  - b. The group discussed limiting the analysis to certain classes
    - i. where therapeutic interchanges are likely to occur
    - ii. for drug classes that were discussed in the patient surveys
      - a. Infections (e.g. HIV, Hepatitis)
      - b. Oncological
      - c. Autoimmune
      - d. Mental Health (e.g. Antipsychotic)
      - e. Neurological (e.g. Epilepsy, M.S.)
    - iii. CHIA will provide summary data to HPC. HPC will do the analysis.
4. Literature review
  - a. The literature review materials collected so far are being summarized
  - b. The question was raised about if PBMs offer enhanced payments to pharmacies to switch drugs, and if this is legal. There was also discussion about the situations where pharmacies and PBMs are the same company, and wondering if there is literature on this. It was agreed to get some more information about this.

5. Surveys
  - a. The patient survey responses are due this week
  - b. The group discussed the Prescriber and Health Plan Surveys
6. Listening Session
  - a. The group confirmed that they wanted the Listening Session to be in the evening and in Boston if possible.
  - b. It is suggested to have speakers limit testimonies to 3 minutes. There is always the option to submit written testimony
7. Next steps and Action items were discussed
8. Adjournment

Respectfully Submitted,

A handwritten signature in black ink that reads "Paul L. Jeffrey". The signature is written in a cursive style with a large, stylized "J".

Paul L. Jeffrey, PharmD

**Materials Distributed at the Meeting:**

- Agenda
- Action Items from last meeting
- Work Plan
- Draft Health Plan Questionnaire
- Draft language for webpage regarding Listening Session